Data

A treatment algorithm evaluating the effect of zoledronic acid on bone mineral density loss after allogeneic stem cell transplantation (BM07)

Health Data Australia Contributor Records
Grigg, Andrew ; Australasian Leukaemia And Lymphoma Group (ALLG) ; Australasian Leukaemia And Lymphoma Group (ALLG)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/F853-WN84&rft.title=A treatment algorithm evaluating the effect of zoledronic acid on bone mineral density loss after allogeneic stem cell transplantation (BM07)&rft.identifier=http://doi.org/10.58109/F853-WN84&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=Dataset includes: Data for 82 patients that had undergone bone marrow transplant Trial assessed the use of zoledronic acid as a treatment to reduce bone mineral density loss Demographic data, diagnostic data, treatment data, outcome data&rft.creator=Grigg, Andrew &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12607000596404&rft_subject=Cancer therapy (excl. chemotherapy and radiation therapy)&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

Dataset includes: Data for 82 patients that had undergone bone marrow transplant Trial assessed the use of zoledronic acid as a treatment to reduce bone mineral density loss Demographic data, diagnostic data, treatment data, outcome data

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Subjects
Cancer therapy (excl. chemotherapy and radiation therapy) |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial

doi : http://doi.org/10.1038/bmt.2017.108

A Risk-Adapted Protocol of Prophylactic Zoledronic Acid Prevents Bone Mineral Density Loss Post Allograft: Results of the ALLG Bm07 Phase II Prospective Trial

doi : https://doi.org/10.1016/j.bbmt.2017.01.065

Australasian Leukaemia And Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Identifiers
Similar data you may be interested in: